US$ 21.28
discovery of glp 1 Glucagon-like peptide-1 receptor: mechanisms and advances in therapy History of glucagon-like peptide-1 receptor
Description
Combining treatments can increase the risk of side effects and may not be safe

LN affects more than 1.7 million people worldwidepredominantly women of colour and those of childbearing ageof whom up to one-third may progress to end-stage kidney disease if untreated

GLP-1 receptor agonists and reduction of cardiometabolic risk: potential underlying mechanisms

Therefore, its imperative to understand what the data tells us about GLP-1 RAs and diabetic retinopathy

Over the past ten years, the use of second-line ADMs has increased significantly
